The molecular genetics of pancreatic cancer

Surgical Oncology

Volumn 6, Issue 1, 1997, Pages 1-18

  Howe, James R ^a   Conlon, Kevin C ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Genetics; Pancreas

Indexed keywords

ACINAR CELL CARCINOMA; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CYTOGENETICS; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; FAMILIAL CANCER; GENE MUTATION; HUMAN; MOLECULAR GENETICS; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; PLOIDY; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; UNITED STATES;

GENES, P53; GENES, RAS; HUMANS; MOLECULAR BIOLOGY; MUTATION; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0030813228     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(97)00001-7     Document Type: Review

References (143)

1. Parker S. L., Tong T., Bolden S. and Wingo P. A. Cancer statistics, 1996. CA Cancer Journal Clinic 1996, 46, 5-27.
2. Conlon K. C., Klimstra D. S. and Brennan M. F. Long term survival following curative resection for pancreatic ductal adenocarcinoma: Clinico-pathological analysis of 5-year survivors. Annals of Surgery 1996, 223, 273-279.
3. Bramhall S. R., Allum S. R., Jones A. G., Allwood A., Cummins C. and Neoptolemus J. P. Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease in the West Midlands: An epidemiological study. British Journal of Surgery 1995, 82, 111-115.
4. Baumel H., Huguier M., Manderscheid J. C., Fabre J. M., Houry S. and Fagot H. Results of resection for cancer of the exocrine pancreas: A study from the French Association of Surgery. British Journal of Surgery 1994, 81, 102-1017.
5. Nitecki S. S., Sarr M. G., Colby T. V. and van Heerden J. A. Long-term survival after resection for ductal adenocarcinoma of the pancreas: Is it really improving? Annals of Surgery 1995, 221, 59-66.
6. Lynch H. T. Genetics and pancreatic cancer. Archives of Surgery 1994, 129, 266-268.
7. Lynch H. T., Fitzsimmons M. L., Smyrk T. C., et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. American Journal of Gastroenterology 1990, 85, 54-60.
8. Ehrenthal D., Haeger L., Griffin T. and Compton C. Familial pancreatic adenocarcinoma in three generations: a case report and review of the literature. Cancer 1987, 59, 1661-1664.
9. Comfort M. W. and Steinberg A. G. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952, 21, 54-63.
10. Castleman B. Case 25-1972, case records of the Massachusetts General Hospital. New England Journal of Medicine 1972, 286, 1353-1359.
11. Gross J. B., Gambill E. E. and Ulrich J. A. Hereditary pancreatitis. Description of a fifth kindred and summary of clinical features. American Journal of Medicine 1962, 33, 358.
12. Davidson P., Costanza D., Swieconek J. A. and Harris J. B. Hereditary pancreatitis: a kindred without gross aminoaciduria. Annals of Internal Medicine 1968, 68, 88-96.
13. Brandi M. L., Marx S. J., Aurbach G. D. and Fitzpatrick L. A. Familial multiple endocrine neoplasia type I: New look at pathophysiology. Endocrinology Reviews 1987, 8, 391-405.
14. Brunt L. M. and Wells S. A. The multiple endocrine neoplasia syndromes. Investigative Radiology 1985, 20, 916-927.
15. Pipeleers-Marichal M., Somers G., Wilems G., Foulis A., Imrie C. and Bishop A. E. Gastrinomas in the duodenum of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. New England Journal of Medicine 1990, 322, 723-727.
16. Larsson K., Skogseid B., Oberg K., Nakamura Y. and Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988, 332, 85-87.
17. Fill W. L., Lamiell J. M. and Polk N. O. The radiographic manifestations of von Hippel-Lindau disease. Radiology 1979, 133, 289-295.
18. Hough D. M., Stephens D. H. and Johnson C. D. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. American Journal of Roentgenology 1994, 162, 1091-1094.
19. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260, 1317-1320.
20. Swift M., Sholman L., Pery M. and Chase C. Malignant neoplasms in the families of patients with ataxia telengectasia. Cancer Research 1976, 36, 209-215.
21. Bergman W., Watson P., deJong J., Lynch H. T. and Fusaro F. M. Systemic cancer and the FAMMM syndrome. British Journal of Cancer 1990, 61, 932-936.
22. Lynch H. T. and Fusaro R. M. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991, 6, 127-131.
23. Mecklin J.-P., Jarvinen H. J. and Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer 1992, 69, 1112-1114.
24. Herrera L., Kakati S., Gibas L., Pietrzak E. and Sandberg A. A. Gardner syndrome in a man with an interstitial deletion of 5q. American Journal of Medical Genetics 1986, 25, 473-476.
25. Johansson B., Bardi G., Heim S., et al. Nonrandom chromosomal rearrangements in pancreatic carcinomas. Cancer 1992, 69, 1674-1681.
26. Bardi G., Johansson B., Pandis N., et al. Karyotypic abnormalities in tumors of the pancreas. British Journal of Cancer 1993, 67, 1106-1112.
27. Griffin C. A., Hruban R. H., Long P. P., Morsberger L. A., Douna-Issa F. and Yeo C. J. Chromosome abnormalities in pancreatic adenocarcinoma. Genes, Chromosomes and Cancer 1994, 9, 93-100.
28. Schutte B., Reynders M. M. J., Wiggers T., et al. Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Research 1987, 47, 5494-5496.
29. Armitage N. C., Ballantyne K. C., Evans D. F., Clarke P., Sheffield J. and Hardcastle J. D. The influence of tumour cell DNA content on survival in colorectal cancer. British Journal of Cancer 1990, 62, 852-856.
30. Yonemura Y., Ooyama S., Sugiyama K., et al. Retrospective analysis of the prognostic significance of DNA ploidy patterns and S-phase fraction in gastric carcinoma. Cancer Research 1990, 50, 509-514.
31. Weger A. R., Graf A. H., Askensten U., et al. Ploidy as prognostic determinant in pancreatic cancer. Lancet 1987, ii, 1031.
32. Bottger T. C., Storkel S., Wellek S., Stockle M. and Junginger T. Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study. Cancer 1994, 73, 63-73.
33. Yeo C. J., Cameron J. L., Lillemoe K. D., et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. Annals of Surgery 1995, 221, 721-733.
34. Forschen R., Remy U., Bevers G., Schauseil S., Hengels K. J. and Borchard F. Prognostic significance of DNA ploidy in adenocarcinoma of the pancreas. Cancer 1993, 71, 3846-3850.
35. Weger A.-R., Falkmer U. G., Schwab G., et al. Nuclear DNA distribution pattern of the parenchymal cells in adenocarcinomas of the pancreas and in chronic pancreatitis. Gastroenterology 1990, 99, 237-242.
36. Alanen K. A., Joensuu H., Klemi P. J. and Nevalainen T. J. Clinical significance of nuclear DNA content in pancreatic carcinoma. Journal of Pathology 1990, 160, 313-320.
37. Hemming A. W., Davis N. L., Kluftinger A., et al. Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67. Journal of Surgical Oncology 1992, 51, 147-152.
38. Yoshimura T., Manabe T., Imamura T., et al. Flow cytometric analysis of nuclear DNA content of duct cell carcinoma of the pancreas. Cancer 1992, 70, 1069-1074.
39. Schlichting E., Clausen O. P. F., Hanssen A. S. and Buanes T. A. Ploidy and survival in resectable pancreatic cancers. European Journal of Surgery 1993, 159, 229-233.
40. Baisch H., Kloppel G. and Reinke B. DNA ploidy and cell-cycle analysis in pancreatic and ampullary carcinoma: Flow cytometry study of formalin-fixed paraffin-embedded tissue. Virchows Archiv 1990, 417, 145-150.
41. Herrera M. F., van Heerden J. A., Katzmann J. A., Weiland L. H., Nagorney D. M. and Ilstrup D. Evaluation of DNA nuclear pattern as a prognostic determinant in resected pancreatic ductal adenocarcinoma. Annals of Surgery 1992, 215, 120-124.
42. Conlon K. C., Marrero A. M., Klimstra D. S., Hameed M. and Brennan M. F. Evaluation of DNA ploidy and cellular proliferative indices as prognostic variables following resection for invasive adenocarcinoma of the pancreas. 49th Annual Cancer Symposium, Society of Surgical Oncology Meeting 1996; (abstract).
43. Bose K. K., Allison D. C., Hruban R. H., et al. A comparison of flow cytometric and absorption cytometric DNA values as prognostic indicators for pancreatic cancer. Cancer 1993, 71, 691-700.
44. Suto T., Sasaki K., Sugai T., Kanno S. and Saito K. Heterogeneity in the nuclear DNA content of cells in carcinomas of the biliary tract and pancreas. Cancer 1993, 72, 2920-2928.
45. Fearon E. R. K-ras gene mutation as a pathogenetic and diagnostic marker in human cancer. Journal of the National Cancer Institute 1993, 85, 1978-1980.
46. Vogelstein B., Fearon E. R., Hamilton S. R., et al. Genetic alterations during colorectal tumor development. New England Journal of Medicine 1988, 319, 525-532.
47. Bos J. L., Fearon E. R., Hamilton S. R., et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327, 293-297.
48. Barbacid M. Ras genes. Annual Reviews in Biochemistry 1987, 56, 779-827.
49. Fujii H., Egami H., Chaney W., Pour P. and Pelling J. Pancreatic ductal adenocarcinomas induced in Syrian hamsters by N-nitrosobis-(2-oxopropyl)amine contain a c-Ki-ras oncogene with a point-mutated codon 12. Molecular Carcinogenesis 1990, 3, 296-301.
50. Cerny W. L., Mangold K. A. and Scarpelli D. G. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Research 1992, 52, 4507-4513.
51. Quaife C. J., Pinkert C. A., Ornitz D. M., Palmiter R. D. and Brinster R. L. Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell 1987, 48, 1023-1034.
52. Forrester K., Almoguerra C., Han K., Grizzle W. E. and Perucho M. Detection of high incidence of K-ras oncogenes during human colorectal tumorigenesis. Nature 1987, 327, 298-303.
53. Finkelstein S. D., Przygodzki R., Pricolo V. E., et al. K-ras-2 topographic genotyping of pancreatic adenocarcinoma. Archives of Surgery 1994, 129, 367-372.
54. Tada M., Yokosuka O., Omata M., Ohto M. and Isono K. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 1990, 66, 930-935.
55. Lemoine N. R., Mayall E. S., Wyllie F. S., et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989, 4, 159-164.
56. Pellegata N. S., Losekoot M., Fodde R., et al. Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer. Anticancer Research 1992, 12, 1731-1735.
57. Scarpa A., Capelli P., Villaneuva A., et al. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. International Journal of Cancer 1994, 57, 167-171.
58. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N. and Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53, 549-554.
59. Yashiro T., Fulton N., Hara H., et al. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 1993, 114, 758-764.
60. Hruban R. H., van Mansfield A. D. M., Offerhaus G. J. A., et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. American Journal of Pathology 1993, 143, 545-554.
61. Grunewald K., Lyons J., Frohlich A., et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. International Journal of Cancer 1989, 43, 1037-1041.
62. Nagata Y., Abe M., Motoshima K., Nakayama E. and Shiku H. Frequent glycine to aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Japanese Journal of Cancer Research 1990, 81, 135-140.
63. Motojima K., Urano T., Nagata Y., Shiku H., Tsunoda T. and Kanematsu T. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. American Journal of Gastroenterology 1991, 86, 1784-1788.
64. Yoshimoto K., Iwahana H., Fukuda A., et al. Ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformational polymorphism. Japanese Journal of Cancer Research 1992, 83, 1057-1062.
65. Motojima K., Tsunoda T., Kanematsu T., Nagata Y., Urano T. and Shiku H. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Annals of Surgery 1991, 214, 657-662.
66. Scarpa A., Capelli P., Zamboni G., et al. Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. American Journal of Pathology 1993, 142, 1163-1172.
67. Scarpa A., Zamboni G., Achille A., et al. ras-family gene mutations in neoplasia of the ampulla of Vater. International Journal of Cancer 1994, 59, 39-42.
68. Howe J. R., Klimstra D. K., Cordon-Cardo C., Paty P. B. Park P. and Brennan M. F. K-ras mutations in adenomas and carcinomas of the ampulla of Vater . Clinical Cancer Research 1997, 3, 129-134.
69. Stork P., Loda M., Bosari S., Wiley B., Poppenhusen K. and Wolfe H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 1991, 6, 857-862.
70. Tada M., Omata M. and Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Research 1990, 50, 1121-1124.
71. Levi S., Urbano-Ispizua A., Gill R., et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Research 1991, 51, 3497-3502.
72. Morohoshi T., Held G. and Kloppel G. Exocrine pancreatic tumors and their histological classification. Histopathology 1983, 7, 645-661.
73. Klimsta D. S., Heffess C. S., Oertel J. E. and Rosai J. Acinar cell carcinoma of the pancreas: a clinicopathologic study of 28 cases. American Journal of Surgical Pathology 1992, 16, 815-837.
74. Hoorens A., Lemoine N. R., McLellan E., et al. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras expression. American Journal of Pathology 1993, 143, 685-698.
75. Shibata D., Almoguera C., Forrester K., et al. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Research 1990, 50, 1279-1283.
76. Urban T., Ricci S., Grange J. D., et al. Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. Journal of the National Cancer Institute 1993, 85, 2008-2012.
77. Kondo H., Sugano K., Fukayama N., et al. Detection of point mutations in the Ki-ras oncogene at codon 12 in pure pancreatic juice for the diagnosis of pancreatic carcinoma. Cancer 1994, 73, 1589-1594.
78. Trumper L. H., Burger B., von Bonin F., et al. Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. British Journal of Cancer 1994, 70, 278-284.
79. Watanabe H., Sawabu N., Ohta H., et al. Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Japanese Journal of Cancer Research 1993, 84, 961-965.
80. Tada M., Omata M., Kawai S., et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Research 1993, 53, 2472-2474.
81. Caldas C., Hahn S. A., Hruban R. H., Redston M. S., Yeo C. J. and Kern S. E. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Research 1994, 54, 3568-3573.
82. Isobe M., Emanuel B. S., Givol G., Oren M. and Croce C. M. Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986, 320, 84-85.
83. Lane D. P. p53, guardian of the genome. Nature 1992, 358, 15-16.
84. Eliyahu D., Michalovitz D., Eliyahu S., Pinhasi-Kimhi O. and Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proceedings of the National Academy of Sciences, U.S.A. 1989, 86, 8763-8767.
85. Baker S. J., Markowitz S., Fearon E. R., Willson J. K. V. and Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990, 149, 912-915.
86. Halevy O., Michalovitz D. and Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990, 250, 113-116.
87. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L. and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358, 80-83.
88. Malkin D., Li F. P., Strong L. C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250, 1233-1238.
89. Hollstein M., Sidransky D., Vogelstein B. and Harris C. C. p53 mutations in human cancers. Science 1991, 253, 49-53.
90. Redston M. S., Caldas C., Seymour A. B., Hruban R. H., da Costa L. and Yeo C. J. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Research 1994, 54, 3025-3033.
91. Scarpa A., Capelli P., Mukai K., et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. American Journal of Pathology 1993, 142, 1534-1543.
92. Casey G., Yamanaka Y., Friess H., et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Letters 1993, 69, 151-160.
93. Barton C. M., Staddon S. L., Hughes C. M., et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. British Journal of Cancer 1991, 64, 1076-1082.
94. Jaskiewicz K., Krige J. E. J. and Thomson J. Expression of p53 tumor suppressor gene, oncoprotein c-erb-2, cellular proliferation and differentiation in malignant versus benign pancreatic lesions. Anticancer Research 1994, 14, 1919-1922.
95. Pellegata N. S., Sessa F., Renault B., et al. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Research 1994, 54, 1556-1560.
96. Nakamori S., Yashima K., Murakami Y., et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Japanese Journal of Cancer Research 1995, 86, 174-181.
97. Leppert M., Dobbs M., Scambler P., et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 1987, 238, 1411-1413.
98. Bodmer W. F., Bailey C. J., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987, 328, 614-616.
99. Fearon E. R. and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767.
100. Kinzler K. W., Nilbert M. C., Su L., et al. Identification of FAP locus genes from chromosome 5q21. Science 1991, 253, 661-665.
101. Nishisho I., Nakamura Y., Myoshi Y., et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991, 253, 665-669.
102. Joslyn G., Carlson M., Thliveris A., et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991, 66, 601-613.
103. Groden J., Thliveris A., Samowitz W., et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66, 589-600.
104. Kinzler K. W., Nilbert M. C., Su L., et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991, 251, 1368-1370.
105. Horii A., Nakaturu S., Miyoshi Y., et al. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Research 1992, 52, 6696-6698.
106. McKie A. B., Filipe M. I. and Lemoine N. R. Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer. International Journal of Cancer 1993, 55, 598-603.
107. Yashima K., Nakamori S., Murakami Y., et al. Mutations in the adenomatous polyposis coli gene in the mutation cluster region: Comparison of human pancreatic and colorectal cancers. International Journal of Cancer 1995, 59, 43-47.
108. Fearon E. R., Cho K. R., Nigro J. M., et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990, 247, 49-247.
109. Hohne M. W., Halatsch M. E. K. G. F. and Weinel R. J. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Research 1992, 52, 2616-2619.
110. Simon B., Weinel R., Hohne M., et al. Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology 1994, 106, 1645-1651.
111. Barton C. M., McKie A. B., Hogg A., et al. Abnormalities of the RB1 and DCC tumor suppressor genes: Uncommon in human pancreatic adenocarcinoma. Molecular Carcinogenesis 1995, 13, 61-69.
112. Stern D. F., Hefferman P. A. and Weinberg R. A. p185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity. Molecular and Cellular Biology 1986, 6, 1729-1740.
113. Yokata J., Yamamoto T., Toyoshima K., et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986, i, 765-766.
114. Slalom D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A. and McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
115. Segato O., King C. R., Pierce J. H., DiFiore P. P. and Aaronson S. A. Different structural alterations up-regulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Molecular and Cellular Biology 1988, 8, 5570-5574.
116. Williams T. M., Weiner D. B., Greene M. I. and Maguire H. C. Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 1991, 59, 46-52.
117. Hall P. A., Hughes C. M., Staddon S. L., Richman P. I., Gulick W. J. and Lemoine N. R. The c-erbB-2 proto-oncogene in human pancreatic cancer. Journal of Pathology 1990, 161, 195-200.
118. Lemoine N. R., Lobresco M., Leung H., et al. The erbB-3 gene in human pancreatic cancer. Journal of Pathology 1992, 168, 269-273.
119. Kamb A., Gruis N. A., Weaver-Feldhaus J., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264, 436-440.
120. Serrano M., Hannon G. J. and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366, 704-707.
121. Cairns P., Polascik T. J., Eby Y., et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Natural Genetics 1995, 11, 210-212.
122. Caldas C., Hahn S. A., da Costa L. T., et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Natural Genetics 1994, 8, 27-32.
123. Liu Q., Yan Y. X., McClure M., Nakagawa H., Fujimura F. and Rustgi A. K. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene 1995, 10, 619-622.
124. Bartsch D., Shevlin D. W., Tung W. T., Kisker O., Wells S. A. and Goodfellow P. J. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes, Chromosomes and Cancer 1995, 14, 189-195.
125. Goldstein A. M., Fraser M. C., Struewing J. P., et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. New England Journal of Medicine 1995, 333, 970-974.
126. Whelan A. J., Bartsch D. and Goodfellow P. J. A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. New England Journal of Medicine 1995, 333, 975-977.
127. Thibodeau S. N., Bren G. and Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993, 260, 816-819.
128. Aaltonen L. A., Peltomaki P., Leach F. S., et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260, 812-816.
129. Fischel R., Lescoe M. K., Rao M. R. S., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolposis colon cancer. Cell 1993, 75, 1027-1038.
130. Leach F. S., Nicolaides N. C. and Papadopoulus N., et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993, 75, 1215-1225.
131. Papadopoulos N., Nicolaides N. C., Wei Y. F., et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263, 1625-1629.
132. Bronner C. E., Baker S. M., Morrison P. T., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994, 368, 258-261.
133. Nicolaides N. C., Papadopoulos N., Liu B.. et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994, 371, 75-80.
134. Lynch H. T., Voorhees G. J., Lanspa S. J., McGreevy P. S. and Lynch J. F. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. British Journal of Cancer 1985, 52, 271-273.
135. Han H. J., Yanagisawa A., Kato Y., Park J. G. and Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Research 1993, 53, 5087-5089.
136. Brentnall T. A., Chen R., Lee J. G., et al. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Research 1995, 55, 4264-4267.
137. Seymour A. B., Hruban R. H., Redston M., et al. Allelotype of pancreatic adenocarcinoma. Cancer Research 1994, 54, 2761-2764.
138. Ruggeri B., Zhang S. Y., Caamano J., DiRado M., Flynn S. D. and Klein-Szanto A. J. P. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992, 7, 1503-1511.
139. Smit V. T. H. B. M., Boot A. J. M., Smits A. M. M., Fleuren G. J., Cornelisse C. J. and Bos J. L. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Research 1988, 16, 7773-7782.
140. Lemoine N. R., Jain S., Hughes C. M., et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992, 102, 230-236.
141. Motojima K., Urano T., Nagata Y., Shiku H., Tsurifune T. and Kanematsu T. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Annals of Surgery 1993, 217, 138-143.
142. Hoshi T., Imai M. and Ogawa K. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. Journal of Surgical Oncology 1994, 55, 84-91.
143. Berrozpe G., Schaeffer J., Peinado M. A., Real F. X. and Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. International Journal of Cancer 1994, 58, 185-191.